Structure Therapeutics Inc. - 8-K Filing

Structure Therapeutics reports Q3 2026 net loss of $144.8 million and maintains $1.2 billion cash position to fund operations through 2028. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $GPCR

Read the full article at SEC EDGAR

More Regulatory news